Department of Gastrointestinal Tract Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Department of Hepato-Biliary-Pancreatic and Transplant Surgery, Fukushima Medical University School of Medicine, Fukushima, Japan.
Mol Cancer Res. 2019 Jun;17(6):1403-1413. doi: 10.1158/1541-7786.MCR-18-0831. Epub 2019 Mar 14.
Immunotherapy against the interaction between programmed cell death 1/programmed cell death ligand 1 (PD-L1) has emerged as a promising strategy for colorectal cancer with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H). The study aimed to identify miRNAs that posttranscriptionally control PD-L1 expression on tumor cells and also regulate immune evasion. A comprehensive miRNA screening using The Cancer Genome Atlas (TCGA) dataset ( = 260) combined with eight different miRNA target prediction programs resulted in the identification of a tumor suppressive miRNA, miR-148a-3p, as a potential negative regulator of PD-L1 expression, particularly in dMMR/MSI-H colorectal cancer. Using multiple cohorts of colorectal cancer, including TCGA data, a microarray dataset ( = 148), and formalin-fixed, paraffin-embedded samples ( = 395), we found that the expression of miR-148a-3p was decreased in dMMR/MSI-H tumors, correlating inversely with PD-L1 levels. We demonstrate that miR-148a-3p directly binds to the 3'-untranslated region of PD-L1, thereby reducing whole-cell and cell surface PD-L1 levels in HCT116 and SW837 cell lines. Overexpression of miR-148a-3p repressed IFNγ-induced PD-L1 expression on tumor cells and consequently diminished T-cell apoptosis in a coculture model of IL2-activated T cells and IFNγ-treated tumor cells. In conclusion, our data support a regulatory mechanism of PD-L1 expression on tumor cells and immune suppression via miR-148a-3p downregulation in colorectal cancer. IMPLICATIONS: This study provides novel evidence that miR-148a-3p negatively regulates tumor cell PD-L1 expression and decreased levels of miR-148a-3p contributes to the immunosuppressive tumor microenvironment.
免疫疗法针对程序性细胞死亡 1/程序性细胞死亡配体 1(PD-L1)的相互作用,已成为具有错配修复缺陷(dMMR)或微卫星不稳定高(MSI-H)的结直肠癌的一种有前途的策略。本研究旨在鉴定在肿瘤细胞上转录后控制 PD-L1 表达并调节免疫逃逸的 miRNA。使用癌症基因组图谱(TCGA)数据集(= 260)与八种不同的 miRNA 靶标预测程序相结合的全面 miRNA 筛选,鉴定出一种肿瘤抑制性 miRNA,miR-148a-3p,作为 PD-L1 表达的潜在负调节剂,特别是在 dMMR/MSI-H 结直肠癌中。使用包括 TCGA 数据、微阵列数据集(= 148)和福尔马林固定、石蜡包埋样本(= 395)在内的多个结直肠癌队列,我们发现 miR-148a-3p 在 dMMR/MSI-H 肿瘤中表达降低,与 PD-L1 水平呈负相关。我们证明 miR-148a-3p 直接结合 PD-L1 的 3'-非翻译区,从而降低 HCT116 和 SW837 细胞系中的全细胞和细胞表面 PD-L1 水平。miR-148a-3p 的过表达抑制了肿瘤细胞中 IFNγ 诱导的 PD-L1 表达,并在 IL2 激活的 T 细胞和 IFNγ 处理的肿瘤细胞共培养模型中减少了 T 细胞凋亡。总之,我们的数据支持 PD-L1 表达的调节机制,以及 miR-148a-3p 通过下调在结直肠癌中抑制肿瘤细胞和免疫抑制的机制。
本研究提供了新的证据,表明 miR-148a-3p 负调控肿瘤细胞 PD-L1 表达,并且 miR-148a-3p 水平降低有助于免疫抑制的肿瘤微环境。